What Avantor (AVTR) said on its Q3 earnings call. Avantor (NYSE:AVTR) reported a return to organic revenue growth in the third quarter of 2026, led by accelerating performance in its VWR Distribution & Services segment and a return to growth in its Bioscience & Medtech Products business. Revenue totaled $1.698 billion, up 5.2% organically and 4.6% on a reported basis from the prior-year quarter. Adjusted EBITDA was $257 million, or a 15.1% margin, while adjusted earnings per share came in at $0.22, above the company's expectations. President and Chief Executive Officer Emmanuel Ligner said the quarter marked an important milestone in the company's Revival program, which is intended to sharpen strategic focus, improve execution and support sustainable growth. "Our third quarter results make a return to organic revenue growth for Avantor," Ligner said. "We have more work to do, but the quarter demonstrates why we believe the action we are taking through Revival are putting us on a path to sustainable growth." VWR growth accelerates as end markets improve. VWR Distribution & Services generated third-quarter revenue of $1.23 billion, representing 5.8% organic growth. The segment's adjusted operating income was $119 million, with an adjusted operating margin of 9.7%. Management said higher volumes drove both sequential and year-over-year growth, reflecting stronger commercial execution and improving end-market conditions. Ligner estimated that approximately half of VWR's growth was attributable to commercial initiatives, including expanded relationships with large customers, gains among small and midsize accounts, and improved e-commerce performance. The company cited continuing momentum among large pharmaceutical and biotechnology customers, which have continued to invest in research and development pipelines. It also reported early signs of improving demand among North American higher-education and early-stage biotechnology customers, as well as strength in certain industrial categories including mining. Geographically, Avantor said demand in the Americas was performing well and activity in Asia was also favorable, though Asia remains a smaller region for the company. Europe continued to lag the Americas and Asia amid high energy costs, pressure on government funding and broader macroeconomic challenges. VWR's operating margin declined both year over year and sequentially, primarily due to sales mix, inflationary pressures and growth investments. Steve Eck, Senior Vice President and Chief Accounting Officer, said the company nevertheless expects modest consolidated margin expansion from the third quarter to the fourth quarter. BMP returns to growth. The Bioscience & Medtech Products, or BMP, segment reported revenue of $465 million, up 3.6% organically from the prior-year period. The segment returned to organic growth despite an approximately 150-basis-point headwind from unusual customer ordering and shipment patterns in its serum business. Process Chemicals delivered high-single-digit growth, supported by improved operations, healthy end markets and order performance. NuSil revenue increased at a low-teens rate as the company executed against what management described as a healthy order book. Fluid Handling and Research and Specialty Chemicals each declined at a low-single-digit rate. BMP adjusted operating income was $123 million, translating to a 26.6% adjusted operating margin. The margin was flat year over year despite inflationary pressure and improved sequentially from the second quarter on higher volume and mix. Ligner said the company has increased manufacturing throughput during 2026 through Revival-related operational initiatives. At one North American production line, Avantor produced more than 25,000 kilograms of product in a single week in early September, exceeding the line's original design-capacity target and reaching nearly 99% overall equipment effectiveness for that week. Management also cited supply-chain planning, digital manufacturing workflows and electronic batch records as initiatives intended to improve product quality, delivery performance and customer service. Ligner said BMP has generated a positive book-to-bill ratio for three consecutive quarters, while Process Chemicals posted high-single-digit order and sales growth year to date. Cash flow, leverage and guidance. Avantor generated $156 million in free cash flow during the quarter, or $169 million excluding cash restructuring costs. The company reduced net debt by $173 million during the period and ended the quarter with $3.235 billion in net debt. Its adjusted net leverage ratio improved to 3.1x from 3.3x in the previous quarter. The company said it remains on track to reduce adjusted net leverage below 3x by year-end. Its capital-allocation priorities include targeted investments to improve customer service and execution, along with continued balance-sheet strengthening. For 2026, Avantor raised its outlook for organic revenue growth to a range of 0.75% to 1.25%. The outlook implies fourth-quarter organic growth of 2.5% to 4.5%, including mid-single-digit growth in VWR and flat to slightly positive organic growth in BMP. The BMP outlook includes an expected roughly 400-basis-point headwind from discrete comparisons, including electronic materials ordering patterns, as well as a more challenging comparison in Process Chemicals. The company expects BMP revenue to rise modestly sequentially in the fourth quarter. Avantor maintained its adjusted EBITDA margin outlook, while forecasting modest margin expansion from the third to fourth quarter. It raised its full-year adjusted EPS outlook to $0.81 to $0.83 and increased projected free cash flow to between $525 million and $550 million. During the question-and-answer session, Chief Financial Officer Todd Garner said the company's pricing realization for 2026 appears to be between 1% and 2%. Management said this remains below inflationary cost increases but represents an improvement in the company's ability to reduce the lag between supplier cost increases and customer pricing. Garner, who joined Avantor as CFO on Sept. 21, said the company is focused on bringing greater transparency, financial rigor and execution discipline to the Revival program. Avantor plans to provide a longer-term financial framework and additional details on its strategy at its Investor Day on Dec. 8. About Avantor (NYSE:AVTR). Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities. Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.

Avantor (NYSE:AVTR) posts earnings results, beats estimates by $0.01 EPS. Posted by Andrew Walz on Oct 28th, 2026 Avantor (NYSE:AVTR - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.21 by $0.01, FiscalAI reports. The company had revenue of $1.70 billion during the quarter, compared to analysts' expectations of $1.64 billion. During the same quarter in the prior year, the company earned $0.22 earnings per share. The business's revenue for the quarter was up 4.6% on a year-over-year basis. Here are the key takeaways from Avantor's conference call: * Avantor returned to organic revenue growth in Q3, with revenue up 5.2% organically to $1.698 billion. VWR grew 5.8%, while Bioscience & Medtech Products returned to growth at 3.6%, supported by improved execution and stronger demand. * Management raised its 2026 outlook, now expecting organic revenue growth of 0.75%-1.25%, adjusted EPS of $0.81-$0.83, and free cash flow of $525-$550 million. The company expects adjusted net leverage to fall below 3.0x by year-end, compared with 3.1x at the end of Q3. * The company cited continued momentum from its Revival program, including improved manufacturing throughput, supply-chain execution, customer service, e-commerce, and AI-enabled commercial tools. BMP also reported positive book-to-bill trends and strong performance in Process Chemicals and NuSil. * Profitability remains pressured by product and customer mix, inflation, and targeted growth investments, particularly in VWR. Management said 2026 pricing of roughly 1%-2% has not fully offset inflation, while Europe remains a weak market and BMP faces approximately 400 basis points of discrete comparison headwinds in Q4. Avantor stock performance. AVTR traded down $0.74 during trading hours on Wednesday, hitting $16.39. 10,506,330 shares of the stock were exchanged, compared to its average volume of 10,117,616. The stock has a 50-day simple moving average of $15.34 and a 200-day simple moving average of $11.18. Avantor has a 12 month low of $7.26 and a 12 month high of $17.45. Key headlines impacting Avantor. Here are the key news stories impacting Avantor this week: * Avantor reported net sales of $1.698 billion, up 4.6% year over year and ahead of the $1.64 billion consensus estimate. Organic sales increased 5.2%, indicating improving underlying demand across the business. * Adjusted earnings were $0.22 per share, exceeding the $0.21 analyst consensus and matching the prior-year result. Diluted GAAP EPS was $0.30. The revenue and earnings beats support the recent increase in AVTR's share price and suggest execution is improving. * Management raised its full-year 2026 organic revenue growth, adjusted EPS and free-cash-flow guidance after results exceeded expectations. Higher guidance is likely the most important bullish development for investors because it improves the outlook for future earnings and cash generation. * Avantor appointed Mikey Santiago as chief information officer to lead its global IT strategy. The change may support operational efficiency over time but is unlikely to materially affect near-term trading. * Barclays maintained a Sell rating and a $15 price target, below AVTR's recent trading level. This signals that some analysts remain concerned about valuation or the durability of the recovery despite the upbeat quarter. Analysts set new price targets. Several analysts have recently weighed in on AVTR shares. Barclays boosted their target price on Avantor from $13.00 to $15.00 and gave the company an "underweight" rating in a report on Wednesday, October 7th. TD Cowen increased their price target on shares of Avantor from $15.00 to $17.00 and gave the company a "hold" rating in a report on Tuesday, October 13th. Royal Bank Of Canada raised their price objective on shares of Avantor from $9.00 to $14.00 and gave the stock a "sector perform" rating in a research note on Thursday, July 30th. Citigroup raised their price objective on Avantor from $9.00 to $11.00 and gave the stock a "neutral" rating in a report on Wednesday, July 8th. Finally, Wall Street Zen raised Avantor from a "hold" rating to a "buy" rating in a research note on Sunday, October 11th. One investment analyst has rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $13.06. About Avantor. Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities. Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications. Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.

Avantor (NYSE:AVTR) will report third-quarter results on Wednesday before market open. Analysts expect revenue to grow 1.1% year on year, a reversal from the 5.3% decline in the same quarter last year. Last quarter, the life sciences company reported revenue of $1.69 billion, flat year on year, beating analyst estimates. It has missed Wall Street's revenue estimates multiple times over the last two years. Among peers, Thermo Fisher's revenue rose 9.1%, and Danaher's rose 8.3%. Thermo Fisher shares fell 1.6% after results, while Danaher's rose 2.4%. Avantor shares are up 11.8% over the last month and trade at $17.10. The average analyst price target is $15.50.